Advances in Metastatic Prostate Cancer - M. Milowsky - 20160622

This lecture discusses some of the advancements in Metastatic Prostate Cancer such as the use of newer hormonal agents and Docetaxel chemotherapy against castration-sensitive metastatic prostate cancer. Learning Outcomes: • Discuss newer hormonal agents in the management of castration-resistant metastatic prostate cancer. • Examine a new role for Docetaxel chemotherapy in the management of castration-sensitive metastatic prostate cancer. • Compare other novel agents in the management of advanced prostate cancer. This lecture was presented as a part of the Medical and Surgical Oncology Series.

Matthew Milowsky MD

6/22/2016 3:30:00 PM